{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 15/80', 'LPC', 'Lysophosphatidylcholine', 'LPD', 'lysophospholipase D', 'LS', 'least square', 'MATE', 'multi drug and toxin extrusion transporter', 'MCID', 'Minimal Clinically Important Difference', 'MMF', 'mycophenolate mofetil', 'MMRM', 'mixed-effects model for repeated measures', 'mRSS', 'modified Rodnan skin score', 'NOAEL', 'no observed adverse effects level', 'NOEL', 'no observed effect level', 'PDE', 'Phosphodiesterase', 'P-gp', 'P-glycoprotein', 'PLA', 'phospholipase A', 'PLC', 'phospholipase C', 'q.d.', 'once daily', 'QTcF', \"QT interval corrected for heart rate using Fridericia's formula\", 'QTcV', \"QT interval corrected for heart rate using Van de Water's formula\", 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SBP', 'systolic blood pressure', 'SCTC', 'Scleroderma Clinical Trials Consortium', 'SOC', 'System Organ Class', 'SUSAR', 'suspected unexpected serious adverse reaction', 'TEAE', 'treatment-emergent adverse event', 'TGF\u00df', 'transforming growth factor \u00df', 'TNF', 'tumor necrosis factor', 'ULN', 'upper limit of normal', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 16/80', 'WOCBP', 'women of childbearing potential', 'Definition of Terms', 'BMI', 'Weight (kg) / (height [m]) 2', 'QTcF', 'QTcF = QT / RR1/3', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 17/80', '1.', 'SUMMARY', 'Objectives:', 'Primary Objective', '-', 'To evaluate the efficacy of GLPG1690 as evaluated by modified Rodnan skin score', '(mRSS) compared to placebo over 24 weeks for the treatment of subjects with systemic', 'sclerosis', 'Secondary Objective', '-', 'To evaluate the safety and tolerability of GLPG1690 compared to placebo over 24 weeks', 'in the treatment of subjects with systemic sclerosis', 'Other Objectives', 'Design:', 'This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center,', 'Phase 2a study designed to evaluate the efficacy, safety, and tolerability of a 600 mg once', 'daily (q.d.) oral dose of GLPG1690 administered over 24 weeks in adult subjects with a', 'confirmed diagnosis of systemic sclerosis. A total of approximately 30 subjects will be', 'randomized in a 2:1 ratio to receive GLPG1690 600 mg q.d. or matching placebo q.d. (for', 'details on sample size, refer to \"Determination of Sample Size\").', 'Rationale:', 'There are currently no approved drugs for the treatment of systemic sclerosis, indicating a', 'high-level unmet medical need. Available literature and preclinical pharmacology data', 'generated by Galapagos suggest that interventions targeting the autotaxin', '(ATX)/lysophosphatidic acid (LPA) pathway could lead to a new class of therapy for disease', 'modification in systemic sclerosis. GLPG1690 is currently in clinical development for the', 'treatment of subjects with idiopathic pulmonary fibrosis (IPF). This study will assess', 'GLPG1690 as a potential first-in-class disease-modifying drug for systemic sclerosis.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}